A B S T R A C T The rapid i.v. administration of digitalis has recently been shown to cause a substantial increase in coronary vascular resistance in the normal heart. This neurogenically mediated decrease in coronary blood flow would be potentially detrimental if it occurred during ischemia. The present study evaluates the effects of i.v. acetylstrophanthidin and digoxin on coronary vascular resistance during acute global ischemia in 29 dogs anesthetized with chloralose and urethane. Under these conditions, 0.5 mg of i.v. acetylstrophanthidin in 15 dogs resulted in erratic increases in coronary vascular resistance. The peak rise was 12 ±5% above control (P < 0.01). In 7 of the 15 dogs, the initial erratic rise in coronary vascular resistance culminated in a steep rise associated with acute elevation in left ventricular end-diastolic pressure, which in four dogs terminated in ventricular fibrillation. During the nonischemic control periods, the peak rise in coronary vascular resistance with acetylstrophanthidin was 16±1% above control (P < 0.01). In five dogs, prior alpha adrenergic receptor blockade with phenoxybenzamine prevented the rise in coronary vascular resistance with acetylstrophanthidin during ischemia. Similar erratic increases in coronary vascular resistance were observed with i.v. digoxin (1 mg) during ischemia in three dogs. In two of these dogs, there was a progressive rise in coronary vascular resistance associated with elevation of left ventricular end-diastolic pressure and ventricular fibrillation. The increase in coronary vascular resistance with digoxin during ischemia was abolished with phenoxybenzamine in two additional dogs.
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INTRODUCTION
Recently, a neurogenic vasoconstrictor effect of digitalis has been demonstrated in the coronary circulation under nonischemic conditions (1, 2) . However, it is not known if this neurogenic vasoconstriction occurs under conditions of myocardial ischemia, because various metabolic changes which result in vasodilation (3, 4) occur in the heart during ischemia. Since digitalis is frequently administered to patients with coronary artery disease, coronary vasoconstriction would produce potentially detrimental effects on an already compromised myocardium.
Balcon et al. (5) have demonstrated that soon after i.v. digitalization of patients with acute myocardial infarctions and left ventricular failure, there was a fall in cardiac output without any change in peripheral vascular resistance. Hodges et al. (6) noted a deterioration of ventricular function shortly after i.v. digitalization in 6 of 10 patients with acute myocardial infarctions and heart failure. Several other studies (7) (8) (9) have also raised the possibility that i.v. digitalis produces only detrimental hemodynamic effects in patients with acute cardiac ischemia.
Thus, the present study was designed to evaluate whether or not neurogenic coronary vasoconstrictor effects of digitalis are present during ischemia and to determine whether these effects, if documented, could be involved in a deterioration of cardiac function after i.v. digitalization.
pirator (Harvard Apparatus Co., Inc., Millis, Mass.) with a mixture of 95% oxygen and 5% carbon dioxide at a rate of 14-18 cycle/min. The blood from two or more donor dogs was used for each experiment. Donor dogs were anesthetized with i.v. sodium methohexital (Brevital, Eli Lilly and Company, Indianapolis, Ind.) and exsanguinated from the femoral artery. 50-100 cm3 of sodium bicarbonate (44 meq/50 cm3) and 20 cm3 of heparin (1,000 U/cm3) were added to the blood from donor dogs.
In the operative animals, a left thoracotomy was performed. Care was taken during surgery to prevent damage to the neural supply to the heart. Coronary sinus blood flow was measured by the method described by Gregg and Fisher (10) . A wide-bore (Bardic no. 16) cannula (C. R. Bard, Inc., Murray Hill, N. J.) was inserted through the right atrial appendage and ligated in place in the most distal part of the coronary sinus. The cannula was held in a horizontal position by a brace (1, 2) . This prevented motion that might lead to transient occlusion of some of the small venous tributaries emptying into the coronary sinus near the right atrium. The position of the cannula was noted at postmortem examination to ensure that there was no occlusion of these small tributaries. Coronary sinus outflow was measured by direct collection of venous blood in graduated cylinders. The coronary sinus effluent was returned to a reservoir to be oxygenated (Fig. 1) .
In cannulating the left coronary artery, care was taken to avoid damage to the surrounding nerve plexus and to avoid stimulation of receptors in the wall. As depicted on the left of Fig. 2 ventricular pressure. Calibration of the dp/dt differentiator was accomplished by supplying a waveform at known slope to the differentiating circuit, which has a time constant of0.001 s and a cutoff at 160 cycle/s.
Coronary vascular resistance (CVR)' was calculated as the ratio ofthe mean coronary artery perfusion and coronary sinus blood flow. Changes in CVR were expressed as percent change from control.
In 10 animals receiving acetylstrophanthidin (0.5 mg), coronary arterial and venous pH, Pco2, P02, potassium, and lactate were determined during nonischemic and ischemic periods. Arterial blood gases, electrolytes, and hematocrit were determined during each experiment and were within the physiologic limits. Statistical analysis was obtained using Student's t test, and results were considered significant when P < 0.05.
Experimental procedure. In 11 dogs, when stability of the preparation had been documented by observation of the systemic hemodynamics and by 10 consecutive 1-min coronary sinus blood flow measurements, 0.5 mg of acetylstrophanthidin was administered intravenously via the brachial vein under nonischemic conditions. After the injection, 1-min coronary sinus blood flow measurements were obtained for each of 30 min. Tracings were obtained at paper speeds of0.25 and 100 mm/s during the time ofeach experiment. An increase in CVR during the nonischemic control period after acetylstrophanthidin administration indicated that the neural control of heart was intact (1, 2) . In these dogs, the coronary artery perfusion pressure was then reduced by lowering the overflow column until the left ventricular end-diastolic pressure was approximately 15 cm H20. Acetylstrophanthidin (0.5 mg) was injected when the coronary sinus blood flow measurements were stable for 10 min, and coronary blood flow determinations were again obtained at 1-min intervals for 30 min. In three of these experiments, after a reflow period of 1 h, acetylstrophanthidin data from a postischemic control period were also obtained. In four additional animals, the sequence was reversed and acetylstrophanthidin data were obtained under conditions of global ischemia first, and control data were obtained after a reflow period of 1 h.
Five dogs with ischemic hearts received acetylstrophanthidin before and after alpha adrenergic receptor blockade with phenoxybenzamine (5 mg/kg). This dose of phenoxybenzamine abolished the coronary vasoconstrictor effects ofmethoxamine (1.0 mg), which was given intravenously immediately before and 30 min after alpha adrenergic receptor blockade. In addition, phenoxybenzamine prevented the rise in systemic arterial pressure produced by methoxamine. Ischemia was produced in three animals without the administration of acetylstrophanthidin, and hemodynamic measurements were again obtained for 30 min.
In four animals, the effects of 1 mg of i.v. digoxin on CVR were evaluated. Hemodynamic and coronary sinus blood flow measurements were made for 1 h after injection. Alpha adrenergic receptor blockade was achieved with phenoxybenzamine (5 mg/kg) before injection of digoxin in two additional dogs. mic conditions in one representative experiment. During the nonischemic control period (left panel of Fig.  3 ), the rise in coronary vascular resistance followed a smooth pattern and the associated hemodynamics were relatively stable. In contrast, during ischemia the increases in coronary vascular resistance were erratic, culminating in a sharp progressive increase in coronary resistance associated with a further elevation of left ventricular end-diastolic pressure (middle panel of Fig.  3 ). The coronary artery perfusion pressure, coronary blood flow, and left ventricular dp/dt were lower during ischemia and left ventricular end-diastolic pressure was higher, as compared with the values ofthese hemodynamics in the nonischemic period. The response of coronary vascular resistance to acetylstrophanthidin during the postischemic control period (right panel of Fig. 3 ) was similar to that of the pre-ischemic control period.
The mean coronary vascular resistance response to i.v. acetylstrophanthidin during the absence of ischemia from 13 dogs is presented in Fig. 4 15 dogs during ischemia. The coronary vascular resistance, coronary blood flow, coronary artery perfusion pressure, and left ventricular dp/dt were significantly lower (P < 0.001) and left ventricular end-diastolic pressure was significantly higher (P < 0.01) during ischemia. In addition, during ischemia, the hearts were in a negative lactate and potassium balance (Fig. 6) . Particularly early during ischemia the coronary venous Pco2 was increased and the coronary venous P02 and pH were decreased (Table III) .
In the group without the progressive rise in coronary vascular resistance, the left ventricular end-diastolic pressure decreased from a mean of 16+1 cm H20 to Effects of i.v. acetylstrophanthidin on coronary resistance under nonischemic and ischemic conditions in the same heart. With ischemia, note the initial erratic changes in coronary vascular resistance terminating in a steep progressive increase. Also note the associated rise in left ventricular end-diastolic pressure. CVR, coronary vascular resistance; CF, coronary blood flow; CAP, coronary artery pressure; MAP, mean aortic pressure; LVEDP, left ventricular end-diastolic pressure; LV dp/dt, the peak of the first derivative of left ventricular pressure. dp/dt increased from 1,800+100 mm Hg/s to 2,400 +100 mm Hg/s (P <0.05) at 20 min after the administration of acetylstrophanthidin. The left ventricular end-diastolic pressure data for each experiment 20k-to 0 are in Table I . However, in the group with progressive increases in coronary resistance, the left ventricular end-diastolic pressure increased from 16+1 cm H20 to 24+2 cm H20 (P <0.01) ( Table I) left ventricular dp/dt decreased from 1,700+100 mm served without the administration ofthis drug. In two of Hg/s to 1,400±100 mm Hg/s (P < 0.05) at the time of these three dogs, when coronary artery perfusion presmaximum rise in the coronary resistance. sure was subsequently reduced further to increase the In three dogs, prolonged ischemia without the ad-severity of the ischemia, there was an immediate inministration of acetylstrophanthidin did not result in crease in left ventricular end-diastolic pressure with an a progressive increase in coronary vascular resistance. associated increase in coronary vascular resistance. The The right and left panels of Fig. 7 illustrate the re-latter data illustrate that in this preparation, the progressults from one animal. The changes in coronary vas-sive steep increase in coronary vascular resistance cular resistance without acetylstrophanthidin ad-could be contributed to by the associated elevation of ministration in these two panels were the greatest ob-left ventricular end-diastolic pressure. FIGURE 6 (A) Reversal of the lactate balance of the heart during ischemia. (B) Reversal of the potassium balance of the heart during ischemia.
In five dogs, prior alpha adrenergic receptor blockade with phenoxybenzamine during ischemia abolished the increases in coronary vascular resistance after acetylstrophanthidin. Fig. 8 is illustrative: the bottom panel shows the greatest change in coronary vascular resistance observed after alpha receptor blockade and acetylstrophanthidin. The difference in response of coronary vascular resistance was due to alpha adrenergic receptor blockade and not to tachyphylaxis, because in two dogs, second injections of acetylstrophanthidin during ischemia, in the absence of alpha receptor blockade, resulted in erratic increases in coronary vascular resistance.
The effects of i.v. digoxin (1.0 mg) on coronary vascular resistance under conditions of low coronary perfusion were evaluated in four dogs. The top four panels of Fig. 9 demonstrate that increases in coronary vascular resistance were observed in all four animals. In two dogs, increases in coronary vascular resistance culminated in ventricular fibrillation. In the fourth panel from the top, the data revealed erratic increases in coronary vascular resistance without ventricular fibrillation. In the second panel of Fig. 9 , the response of coronary vascular resistance was smooth and rather sustained, resembling that seen when digoxin is injected under nonischemic conditions (1, 2) . It is of interest that the left ventricular end-diastolic pressure in this dog was 9 cm H20, the lowest value occurring in any of the hearts in this present study in which tt Lv dp/dt = left ventricular peak dp/dt. In two additional dogs, prior alpha adrenergic receptor blockade during ischemia abolished the increases in coronary resistance produced by digoxin (lower two panels of Fig. 9 ). Stability of the left ventricular end-diastolic pressure and left ventricular dpldt were noted in these two dogs after the injection of digoxin.
DISCUSSION
The data demonstrate that the rapid i.v. administration of digitalis results in vasoconstriction of the coronary circulation during acute global ischemia in the canine heart. The mechanism of this vasoconstriction is neurogenic and appears mediated through stimulation of alpha adrenergic receptors. The increase in coronary vascular resistance during ischemia can be associated with rapid deterioration of left ventricular function.
The coronary vasoconstriction which occurs during ischemia after digitalis administration appears to be the result of alpha adrenergic receptor stimulation and not some other property of ischemia. The evidence for this is twofold. First, during control ischemia experiments in which digitalis was withheld, minimal to no vasoconstriction was observed. Second, the coronary vasoconstriction with digitalis was abolished by pharmacologic blockade of alpha adrenergic receptors. Thus, the mechanism of the neurogenic vasoconstrictor response during acute global ischemia of the heart is similar to that in nonischemic skeletal muscle (11) and in the nonischemic coronary circulation (1, 2) .
It has been demonstrated in paced and nonpaced beating hearts and in fibrillating hearts that stimulation of the stellate ganglia and the intracoronary administration of norepinephrine both produce an initial coronary vasoconstriction followed by vasodilation (12) . The delayed vasodilation was due to enhanced metabolic activity associated with increases in left ventricular dp/dt, heart rate, and systemic arterial pressure. Blockade of this latter myocardial response with beta adrenergic receptor antagonist reversed the vasodilator response to a sustained vasoconstriction (13) . Also, in skeletal muscle Remensnyder et al. (14) demonstrated that neurogenic vasoconstriction could be completely abolished by exercise. Similarly, Donald et al. (15) showed that during exercise in dogs the hind limb blood flow increased in direct relation to the severity of exercise both in presence of an intact lumbar sympathetic chain and after lumbar sympathetectomy. However, stimulation of the lumbar sympathetic chain in the exercising hind limb produced a significant reduction in blood flow. Similarly, in the present study the neurogenic coronary vasoconstriction produced by digitalis persisted despite various metabolic alterations associated with is- and severity of regional myocardial ischemia. This has been presumed to be due entirely to an increase in inotropy with an associated increase in myocardial oxygen demand. In our studies, the lack of change in left ventricular end-diastolic pressure and left ventricular dpldt with the administration of digoxin suggests the possibility that this drug may increase ischemia solely secondary to neurogenic coronary vasoconstriction. However, one should be cautious in extrapolating the results of the present study in which the ischemia was global and the degree of ischemia which was produced was limited by the overall function of the heart to the clinical situation; it is possible that the metabolic consequences of severe regional ischemia combined with left ventricular failure may be sufficient to prevent the neurogenic coronary vasoconstrictor effects of digitalis. Nevertheless, the present study establishes that the acute administration of digitalis is capable of producing neurogenic coronary vasoconstriction under conditions of ischemia and elevated ventricular end-diastolic pressure.
